BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) will be presenting at the 2010 BIO CEO & Investor Conference. Hosted by the Biotechnology Industry Organization (BIO), the 12th Annual CEO & Investor Conference will take place February 8-9 at the Waldorf-Astoria in New York.

Stephen M. Simes, BioSante’s president & CEO, will speak on Tuesday February 9, 2010 at 11:30 am EST. He will provide an overview of the company, as well as an update on LibiGel ® (testosterone gel). A live audio webcast of Mr. Simes’ remarks may be accessed at www.biosantepharma.com/Webcasts.php and a replay will be available at the same link.

Mr. Simes also will participate as a panelist on a business workshop panel focused on mergers and acquisitions. The panel is titled M&A: Prospects for 2010 and will be held on Monday, February 8, 2010 from 12:00 pm EST to 1:00 pm EST.

About The BIO CEO & Investor Conference

Now in its twelfth year, the BIO CEO & Investor Conference 2010 is the largest investor conference focused on the biotechnology industry. The conference provides a forum for public and private equity investors, research analysts, investment bankers and senior-level industry executives to learn about and discuss investment trends and investment opportunities in the biotechnology industry. This year’s conference will feature corporate presentations from more than 120 companies, workshops featuring leading experts on specific therapeutic and technology topics, plenary and panel sessions on timely business issues and industry trends, many opportunities to schedule one-on-one meetings, as well as numerous networking opportunities. For more information, visit www.ceo.bio.org.

About BioSante Pharmaceuticals, Inc.

BioSante is a specialty pharmaceutical company focused on developing products for female sexual health, menopause, contraception and male hypogonadism. BioSante’s lead products include LibiGel ® (transdermal testosterone gel) in Phase III clinical development by BioSante under a U.S. Food and Drug Administration (FDA) SPA (Special Protocol Assessment) for the treatment of female sexual dysfunction (FSD), and Elestrin™ (estradiol gel) developed through FDA approval by BioSante, indicated for the treatment of moderate-to-severe vasomotor symptoms associated with menopause, currently marketed in the U.S. Also in development are Bio-T-Gel™, a testosterone gel for male hypogonadism, licensed to Teva Pharmaceuticals (NASDAQ: TEVA) and an oral contraceptive in Phase II clinical development using BioSante patented technology. The current market in the U.S. for estrogen and testosterone products is approximately $2.5 billion and for oral contraceptives approximately $3 billion. The company also is developing its calcium phosphate technology (CaP) for aesthetic medicine (BioLook™), as a vaccine adjuvant, including for an H1N1 (swine flu) vaccine, and drug delivery. In addition, BioSante will seek opportunities for its GVAX cancer immunotherapies, 2A/Furin and other technologies. Additional information is available online at: www.biosantepharma.com.

Copyright Business Wire 2010